Thomas B. Russell
Experienced in Ewing Sarcoma
Experienced in Ewing Sarcoma

Overview

Thomas Russell is a Hematologist and a Pediatrics provider in Charlotte, North Carolina. Dr. Russell is rated as an Experienced provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Neuroblastoma, Burkitt Lymphoma, Acute Lymphoblastic Leukemia (ALL), Leukemia, and Bone Marrow Aspiration. Dr. Russell is currently accepting new patients.

His clinical research consists of co-authoring 19 peer reviewed articles and participating in 32 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 2 clinical trials in the study of Ewing Sarcoma.

Graduate Institution
The University Of New Mexico
Residency
The University of New Mexico
Specialties
Pediatrics
Hematology
Oncology
Licenses
Pathology in NC
Board Certifications
American Board Of Pediatrics, Pediatric Hematology And Oncology
American Board Of Pediatrics
Fellowships
Oregon Health & Science University
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Atrium Health Levine Children’s Cancer & Blood Disorders, a facility of Carolinas Medical Center
1001 Blythe Blvd., Suite 3000, Charlotte, NC 28203

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


32 Clinical Trials

A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Neuroblastoma Biology Studies
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Renal Tumors Classification, Biology, and Banking Study
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
View 28 Less Clinical Trials
Similar Doctors
Javier E. Oesterheld
Advanced in Ewing Sarcoma
Hematology | Oncology
Advanced in Ewing Sarcoma
Hematology | Oncology

Atrium Health Levine Children’s Cancer & Blood Disorders, A Facility Of Carolinas Medical Center

1001 Blythe Blvd., Suite 3000, 
Charlotte, NC 
 (0.1 miles away)
Experience:
25+ years
Languages Spoken:
English, Spanish
Accepting New Patients
Offers Telehealth

Javier Oesterheld is a Hematologist and an Oncologist in Charlotte, North Carolina. Dr. Oesterheld has been practicing medicine for over 25 years and is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Ewing Sarcoma, Osteosarcoma, and Bone Marrow Transplant. Dr. Oesterheld is currently accepting new patients.

Distinguished in Ewing Sarcoma
Hematology Oncology | Hematology | Oncology
Distinguished in Ewing Sarcoma
Hematology Oncology | Hematology | Oncology

Wake Forest University Health Sciences

557 Brookdale Dr, 
Statesville, NC 
 (41.1 miles away)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Jing Li is a Hematologist Oncology specialist and a Hematologist in Statesville, North Carolina. Dr. Li is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Thrombocytopenia, Colorectal Cancer, Familial Colorectal Cancer, and Ewing Sarcoma. Dr. Li is currently accepting new patients.

Advanced in Ewing Sarcoma
Oncology | Hematology Oncology
Advanced in Ewing Sarcoma
Oncology | Hematology Oncology
15830 Ballantyne Medical Pl, Ste 200, 
Charlotte, NC 
 (10.3 miles away)
Languages Spoken:
English

Michael Livingston is an Oncologist and a Hematologist Oncology provider in Charlotte, North Carolina. Dr. Livingston is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, and Myxoid Liposarcoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Russell's expertise for a condition
ConditionClose
        View All 20 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile